Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down - What's Next?

Key Points

• Zealand Pharma A/S shares experienced a significant gap down, opening at $71.60 after closing at $77.42, marking a drop of 4.5%.
• Despite the recent dip, multiple equities analysts have given the stock a positive outlook, with five analysts rating it as a Strong Buy.
• In its last quarterly earnings, Zealand Pharma reported an EPS of $16.06, which fell short of the consensus estimate of $16.72, alongside a revenue that was notably lower than analyst estimates.

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $77.42, but opened at $71.60. Zealand Pharma A/S shares last traded at $71.60, with a volume of 209 shares trading hands.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Zacks Research raised Zealand Pharma A/S from a "strong sell" rating to a "hold" rating in a report on Monday, September 15th. Barclays raised Zealand Pharma A/S to a "strong-buy" rating in a report on Monday, July 7th. BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st. Finally, Wells Fargo & Company raised Zealand Pharma A/S to a "strong-buy" rating in a report on Thursday, July 24th. Five analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Strong Buy".

Zealand Pharma A/S Stock Down 4.5%

The company has a debt-to-equity ratio of 0.02, a current ratio of 15.09 and a quick ratio of 15.08. The firm has a market cap of $5.08 billion, a price-to-earnings ratio of 5.03 and a beta of 0.74. The business has a fifty day simple moving average of $68.79 and a 200 day simple moving average of $64.63.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported $16.06 EPS for the quarter, missing the consensus estimate of $16.72 by ($0.66). Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 67.06%. The company had revenue of $1.43 billion during the quarter, compared to analyst estimates of $9.18 billion. As a group, equities analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.